Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Weijing Sun, MD, FACP, Reviews Trends in Gastrointestinal Cancer

August 17, 2022
By Weijing Sun, MD, FACP
Publication
Article
OncologyONCOLOGY Vol 36, Issue 8
Volume 36
Issue 8
Pages: 481

“...we don’t focus on survivorship enough. It’s important to understand the other factors involved in surviving besides just a treatment.”

Current treatment options in gastrointestinal cancer continue to evolve, with longer survival times leading investigators to focus more and more on patients’ quality of life and survivorship care.

Weijing Sun, MD, FACP, discussed new treatments, trends in the space, diversity in clinical trials, and how an increased focus on survivorship is changing the needs of patients and investigators in an interview with ONCOLOGY®.

Q:Can you give a brief overview of updates in the gastrointestinal space?

Sun: Cholangiocarcinoma [had seen a lot of progress recently, with treatments for] molecular markers or mutation drivers, such as FGFR and IDH1 mutations becoming standardized to a certain level after the FDA approved some drugs. Most studies show the advantage of those [precision] approaches, so it’s an important [characteristic] we’re looking for. There’s not a huge [amount of data] with these studies, but that information is important because each mutation allows for a personalized medicine [approach]. For gastric and esophageal cancer, over the past 2 or 3 years we confirmed that immune checkpoint inhibitors are playing a major role in metastatic disease.

Q:What trends have you observed?

Sun: One would be quality of life vs treatment [outcomes]. In some diseases like stomach disease or gastric cancer, [guidelines] are updated all the time. We focus on the overall survival and the response rate. Nowadays, we have data showing quality of life makes people survive longer. I’m glad to see [survival increasing in] many of these studies, through all different kinds of support. This type of research is important for the future because the longer the patient is surviving, the quality of life [increasingly becomes a concern]. I see it as something to focus on.

An area is in gastrointestinal cancer we don’t talk about much is diversity, which means [we end up with] underrepresented or underserved populations. We want to make a difference; we see more research heading in that direction. With this information, we can deliver better care, we can deliver more focus for those underserved populations, and their outcomes can catch up with [those in the overall populations].

Q:What are some unmet needs in the gastrointestinal cancer field?

Sun: Pancreatic cancer is a [lesser investigated malignancy than other] diseases. We still don’t know everything; we are far away from [uncovering it all] compared with other diseases. We need to put in more effort, especially regarding tumor biology and the tumor microenvironment because this can tell us the mutations that are important and play an important role.

The other thing is we need a more comprehensive understanding of the diseases, even in survivorship. It’s important because certain patients are living [longer lives], and we don’t focus on survivorship enough. It’s important to understand the other factors involved in surviving besides just a treatment.

Reference

Sun W, Saeed A, Taiseer M, et al. A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach. J Clin Oncol. 2022;40(suppl 16):4047. doi:10.1200/JCO.2022.40.16_suppl.4047

Download Issue PDFDownload PDF
Articles in this issue

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy
Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas
Weijing Sun, MD, FACP, Reviews Trends in Gastrointestinal Cancer
Weijing Sun, MD, FACP, Reviews Trends in Gastrointestinal Cancer
The High Cost of Oral Anticancer Drugs: What Does the Future Hold?
The High Cost of Oral Anticancer Drugs: What Does the Future Hold?
Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
Advertisement

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 13th 2025
Article

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.

Chemoradiation Shows Responses Across Dose Levels in Anal Cancer

Russ Conroy
May 9th 2025
Article

Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.


Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Related Content
Advertisement

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 13th 2025
Article

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.

Chemoradiation Shows Responses Across Dose Levels in Anal Cancer

Russ Conroy
May 9th 2025
Article

Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.


Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.